No Data
Leadman: 2024 Annual Report Summary
Leadman: 2024 Annual Report
Beijing Leadman Biochemistry (300289.SZ) announced its 2024 performance, reporting a loss of 75.1013 million yuan.
Beijing Leadman Biochemistry (300289.SZ) released its annual report for 2024, reporting a revenue of 0.37 billion yuan, and...
Beijing Leadman Biochemistry (300289.SZ) has been re-certified as a high-tech enterprise.
Gelonghui reported on February 11 that Beijing Leadman Biochemistry (300289.SZ) announced that it recently received the "High-tech Enterprise Certificate" jointly issued by the Peking Municipal Science and Technology Commission, the Peking Municipal Finance Bureau, and the State Taxation Administration's Peking Taxation Bureau. The company has once again passed the qualification for high-tech enterprises, with the certificate number GS202411000092, issued on December 19, 2024, and is valid for three years.
Leadman: 2024 performance forecast
Beijing Leadman Biochemistry (300289.SZ): Currently, there are no registered certificates for products related to Monkeypox Virus Testing.
On January 15, Gelonghui reported that Beijing Leadman Biochemistry (300289.SZ) stated on the investor interaction platform that the company currently has not applied for any registration certificates for products related to Monkeypox Virus Testing. As for the specific review timeline of patents related to Monkeypox Virus Testing, please refer to the information released by the relevant departments, and the company will continue to closely monitor related developments.